Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

xpectations. We are proud to have contributed to Nycomed's development into a world-class pharmaceutical company with a strong market position and product pipeline. I feel confident that Takeda will be able to further build upon Nycomed's potential and create an even stronger company with a global market presence," said Kristoffer Melinder, Managing Partner of NC Advisory AB, advisor to the Nordic Capital funds.

1.  Expected benefits

  • Strong fit with Takeda’s sustainable growth strategy
  • Strengthens pan-European platform
  • Leverages Nycomed’s emerging markets strength to drive growth
  • Allows Takeda to maximize the value of its portfolio supported by enhanced development expertise and commercialization capability in Europe and emerging markets
  • Provides a significant growth driver with roflumilast (Daxas® tradename in Europe)
  • Immediate financial contribution(*)
  • More than 30% increase of annual revenue
  • More than 40% increase of operating income (excluding special factors derived from business acquisition)
  • More than 30% increase of EPS (excluding special factors derived from business acquisition)

  • (*) Comparison with the original outlook of fiscal 2013 in 2011-2013 Mid-Range Plan, announced on May 11, 2011

  • Complementary cultures and diverse talent pool

  • 2.  Acquisition summary (1)

    Acquiring company: Takeda Pharmaceutical Company Limited(2)

    Shareholders of Nycomed include Nordic Capital Funds V and VI, DLJ Merchant Banking Partners (a Credit Suisse affiliate), Coller International Partners IV and V, and Avista Capital Partners, Nycomed’s management and employees team(3)

    Number of outstanding shares: 13,778,110 shares (as of December 31, 2010)(4)

    Payment: Cash (Takeda will finance part of the transaction through a loan for about 600 to 700 billion yen)(5)

    Acquisition amount: &
    '/>"/>

    SOURCE Takeda Pharmaceutical Company Limited
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
    2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
    3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
    4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
    5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
    6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
    7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
    8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
    9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
    10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
    11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... MELVILLE, N.Y. , June 29, 2015 /PRNewswire/ ... ), the world,s largest provider of health care ... and medical practitioners, announced today that it has ... by the Association of Hispanic Healthcare Executives (AHHE), ... and policies to increase the presence of Hispanic ...
    (Date:6/29/2015)... 29, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... to the Russell 2000® Small Cap, Russell 3000®, and ... at the close of trading on June 26, 2015 ... of U.S. and global indexes. Sorrento is already a ... About the Russell Indexes. Russell indexes ...
    (Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... novel blood-draw technology has received CE Mark (Conformite ... from the European Union. This regulatory milestone further ... to one of the most common procedures in ... Velano Vascular,s proprietary device reduces the need ...
    Breaking Medicine Technology:Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 2Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 3Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 4Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 5Henry Schein Selected As Corporation of the Year By The Association of Hispanic Healthcare Executives 6Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes 2Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes 3Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2
    ... Inc. (the "Company") (Nasdaq: CMED ), a leading China-based ... the fourth fiscal quarter ("4Q FY2010") and the full fiscal year ... Highlight sFor   the   ...   31,   2010March   31, ...
    ... Medical, Inc. will sell its BioTREK technology platform, which has ... the firm Finn, Warnke & Gayton, LLP to be liquidated ... bid sale of June 10, 2011. BioTREK ... to create a family of percutaneous devices for repair or ...
    Cached Medicine Technology:China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 2China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 3China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 4China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 5China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 6China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 7China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 8China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 9China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 10China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 11China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 12China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 13China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 14China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 15China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 16China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 17China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 18China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 19China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 20China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 21China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 22China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 23China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 24China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results 25NMT Medical, Inc. to Sell BioTREK Technology Platform at Its Sealed Bid Sale on Friday, June 10, 2011 at Twelve O'Clock Noon 2
    (Date:6/29/2015)... Provo, Utah (PRWEB) , ... June 30, 2015 ... ... and corporate training, has released a new website intended for executives and administrators ... significantly enhance user experience, and the final product is a result of comprehensive ...
    (Date:6/29/2015)... ... June 29, 2015 , ... ... desire to educate readers and potential patients about a variety of plastic surgery ... cosmetic dentistry and more. , It has been the main focus of Cosmetic ...
    (Date:6/29/2015)... ... June 29, 2015 , ... ... to its multidisciplinary group of physicians and specialists. Dr. Cook is experienced with ... healthcare in hopes of achieving outstanding medical outcomes. , “We are very excited ...
    (Date:6/29/2015)... ... June 29, 2015 , ... ... Martin Del Campo is their newest FAA-certified medical examiner in the city of ... for all fledging pilots seeking to obtain their physical aviation certificates. Pilots hoping ...
    (Date:6/29/2015)... Wisconsin (PRWEB) , ... June 29, 2015 , ... ... with the news that the European Medicines Agency (EMA) has granted accelerated approval ... “Melanoma remains a global public health threat and the approval of nivolumab for ...
    Breaking Medicine News(10 mins):Health News:Career Step Launches New Website to Better Meet Needs of Partners, Clients and Others Searching for Corporate Training Solutions 2Health News:Board of Advisors Now Coming to Cosmetic Town 2Health News:Healthpointe in La Tijera Proudly Announces the Addition of a New Chiropractor 2Health News:Healthpointe in La Tijera Proudly Announces the Addition of a New Chiropractor 3Health News:Healthpointe Now Offering FAA Physical Exams in San Bernardino County 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
    ... overweight and obese people getting? More than many ... Case Western Reserve University,s Frances Payne Bolton School of ... Journal of the American Academy of Nurse Practitioners ... individuals." Deborah Walton Smith, who is now a ...
    ... failure who repress their emotions, especially anger, are more ... depression associated with knowledge about their disease, according to ... study influenced how depressed or anxious they felt. The ... more likely they were to have symptoms of depression ...
    ... Not a single person identified with autism or asperger,s ... they had the condition, research led by the University ... Professor of Psychiatry at the University of Leicester, the ... males, those without higher educational qualifications, and those living ...
    ... Children,s health problems caused by air pollution, exposure to toxic ... billion in 2008, a new study finds. That was ... compared with 2.8 percent in 1997, said researchers from the ... the cost of childhood cancer and chronic conditions such as ...
    ... studies have shown that a 64-detector CT angiography ... image but considerably reduced patient radiation dose when ... being presented at the 2011 American Roentgen Ray ... in the Department of Radiology at the University ...
    ... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) -- The ... more than 12 percent between 2001 and 2009, U.S. health ... people, according to the U.S. Centers for Disease Control and ... million Americans have asthma "and that number, unfortunately, is rising," ...
    Cached Medicine News:Health News:Making the move to exercise for overweight and obese people 2Health News:More knowledge not always helpful for women dealing with heart disease 2Health News:More knowledge not always helpful for women dealing with heart disease 3Health News:More knowledge not always helpful for women dealing with heart disease 4Health News:'Most adults with autism go undiagnosed' -- new findings 2Health News:'Most adults with autism go undiagnosed' -- new findings 3Health News:Treating Kids for Environmental Ills Costs U.S. $76B a Year 2Health News:Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients 2Health News:Number of Americans With Asthma Keeps Rising 2Health News:Number of Americans With Asthma Keeps Rising 3
    Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
    Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
    Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
    ... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
    Medicine Products: